Chronic osteomyelitis

Current Infectious Disease Reports

Volumn 14, Issue 5, 2012, Pages 566-575

  Uçkay, Ilker ^a,b   Jugun, Kheeldass ^a   Gamulin, Axel ^a   Wagener, Joe ^a   Hoffmeyer, Pierre ^a   Lew, Daniel ^a,b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Antibiotic therapy; Duration; Osteomyelitis; Penetration; Recurrence; Surgery

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; FUSIDIC ACID; LINEZOLID; RIFAMPICIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; BONE RESECTION; CHRONIC DRUG ADMINISTRATION; CHRONIC OSTEOMYELITIS; CLINICAL EVALUATION; DEBRIDEMENT; DIABETIC FOOT; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG EFFICACY; DRUG PENETRATION; DRUG TREATMENT FAILURE; HUMAN; HYPERBARIC OXYGEN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; PATHOGENESIS; RECURRENT DISEASE; REMISSION; REVIEW; SACROILIITIS; SEQUESTROTOMY; SKIN INFECTION; SOFT TISSUE INFECTION; TREATMENT DURATION;

EID: 84870556933     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-012-0286-0     Document Type: Review

References (97)

1. Lazzarini L, Lipsky BA, Mader JT. Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials? Int J Infect Dis. 2005;9:127-38.
2. Lew DP, Waldvogel FA. Osteomyelitis. Lancet. 2004;364:369-79.
3. Whitehouse JD, Friedman ND, Kirkland KB, et al. The impact of surgical-site infections following orthopedic surgery at a community hospital and a university hospital: adverse quality of life, excess length of stay, and extra cost. Infect Control Hosp Epidemiol. 2002;23:183-9.
4. Uçkay I, Harbarth S, Peter R, et al. Preventing surgical site infections. Expert Rev Anti Infect Ther. 2010;8:657-70.
5. Rod-Fleury T, Dunkel N, Assal M, et al. Duration of post-surgical antibiotic therapy for adult chronic osteomyelitis: a single-centre experience. Int Orthop. 2011;35:1725-31. Retrospective singlecentre study regarding the optimal duration of antibiotic treatment concomitant to surgery in implant-free chronic osteomyelitis. Short regimens do not enhance recurrence risk.
6. Paakkonen M, Peltola H. Antibiotic treatment for acute haematogenous osteomyelitis of childhood: moving towards shorter courses and oral administration. Int J Antimicrob Agents. XXX,38:273-280. A state-of-the art paper concerning short antibiotic regimens for pediatric cases.
7. Waldvogel FA, Medoff G, Swartz MN. Treatment of osteomyelitis. N Engl J Med. 1970;283:822.
8. Cierny 3rd G, Mader JT, Penninck JJ. A clinical staging system for adult osteomyelitis. Clin Orthop Relat Res. 2003;414:7-24.
9. Legout L, Assal M, Rohner P, et al. Successful treatment of Candida parapsilosis (fluconazole-resistant) osteomyelitis with caspofungin in a HIV patient. Scand J Infect Dis. 2006;38:728-30.
10. Blyth CC, Gomes L, Sorrell TC, et al. Skull-base osteomyelitis: fungal vs. bacterial infection. Clin Microbiol Infect. 2011;17:306-11.
11. Uçkay I, Pittet D, Vaudaux P, et al. Foreign body infections due to Staphylococcus epidermidis. Ann Med. 2009;41:109-19. Clinical problems dealing with biofilms in implant-Associated infections.
12. Karamanis EM, Matthaiou DK, Moraitis LI, Falagas ME. Fluoroquinolones versus beta-lactam based regimens for the treatment of osteomyelitis: a meta-Analysis of randomized controlled trials. Spine. 2008;33:297-304.
13. Hernigou P, Daltro G, Flouzat-Lachaniette CH, et al. Septic arthritis in adults with sickle cell disease often is associated with osteomyelitis or osteonecrosis. Clin Orthop Relat Res. 2010;468:1676-81.
14. Al-Tawfiq JA. Bacteroides fragilis bacteremia associated with vertebral osteomyelitis in a sickle cell patient. InternMed. 2008;47:2183-5.
15. Haidar R, Der Boghossian A, Atiyeh B. Duration of post-surgical antibiotics in chronic osteomyelitis: empiric or evidence-based? Int J Infect Dis. 2010;14:752-8.
16. Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. Plast Reconstr Surg. 2006;117:212-38.
17. Beals RK, Bryant RE. The treatment of chronic open osteomyelitis of the tibia in adults. Clin Orthop Relat Res. 2005;433:212-7.
18. Ciampolini J, Harding KG. Pathophysiology of chronic bacterial osteomyelitis. Why do antibiotics fail so often? Postgrad Med J. 2000;76:479-83.
19. Hannan CM, Attinger CE. Special considerations in the management of osteomyelitis defects (diabetes, the ischemic or dysvascular bed, and irradiation). Semin Plast Surg. 2009;23:132-40.
20. Spellberg B, Lipsky BA. Systemic antibiotic therapy for chronic osteomyelitis in adults. Clin Infect Dis. 2012;54:393-407. Summary of antibiotic administration for osteomyelitis. Favors early switch to oral regimens.
21. Costerton W, Veeh R, Shirtliff M, et al. The application of biofilm science to the study and control of chronic bacterial infections. J Clin Invest. 2003;112:1466-77.
22. Ceri H, Olson ME, Stremick C, et al. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol. 1999;37:1771-6.
23. Lew D, Schrenzel J, François P, Vaudaux P. Pathogenesis, prevention, and therapy of staphylococcal prosthetic infections. Curr Clin Top Infect Dis. 2001;21:252-70.
24. Calhoun JH, Manring MM. Adult osteomyelitis. Infect Dis Clin North Am. 2005;19:765-86.
25. Uçkay I, Ferry T, Stern R, et al. Use of serum antistreptolysin-Otiters in the microbial diagnosis of orthopedic infections. Int J Infect Dis. 2009;13:421-4.
26. Bernard L, Uçkay I, Vuagnat A, et al. Two consecutive deep sinus tract cultures predict the pathogen of osteomyelitis. Int J Infect Dis. 2009;14:390-3.
27. Mackowiak PA, Jones SR, Smith JW. Diagnostic value of sinustract cultures in chronic osteomyelitis. JAMA. 1978;239:2772-5.
28. Parsons B, Strauss E. Surgical management of chronic osteomyelitis. Am J Surg. 2004;188:57-66.
29. Boda A. Antibiotic irrigation-perfusion treatment for chronic osteomyelitis. Arch Orthop Trauma Surg. 1979;95:31-5.
30. Berendt T, Byren I. Bone and joint infection. Clin Med (London, England). 2004;4:510-8.
31. Kinik H, KaradumanM. Cierny-Mader Type III chronic osteomyelitis: the results of patients treated with debridement, irrigation, vancomycin beads and systemic antibiotics. Int Orthop. 2008;32:551-8.
32. Tan Y, Wang X, Li H, et al. The clinical efficacy of the vacuumassisted closure therapy in the management of adult osteomyelitis. Arch Orthop Trauma Surg. 2011;131:255-9.
33. Beckles VL, Jones HW, Harrison WJ. Chronic haematogenous osteomyelitis in children: a retrospective review of 167 patients in Malawi. J Bone Joint Surg Br. 2010;92:1138-43.
34. Berendt AR. Counterpoint: hyperbaric oxygen for diabetic foot wounds is not effective. Clin Infect Dis. 2006;43:193-8.
35. Andel H, Felfernig M, Andel D, et al. Hyperbaric oxygen therapy in osteomyelitis. Anaesthesia. 1998;53:68-9.
36. Bernard L, Legout L, Zürcher-Pfund L, et al. Six weeks of antibiotic treatment is sufficient following surgery for septic arthroplasty. J Infect. 2010;61:125-32.
37. Conterno LO, da Silva Filho CR. Antibiotics for treating chronic osteomyelitis in adults. Cochrane Database Syst Rev. 2009;3: CD004439. Metaanalysis regarding antibiotic duration and administration form in adult chronic osteomyelitis.
38. Mader JT, Shirtliff ME, Bergquist SC, Calhoun J. Antimicrobial treatment of chronic osteomyelitis. Clin Orthop Relat Res. 1999;360:47-65.
39. Matthews PC, Conlon CP, Berendt AR, et al. Outpatient parenteral antimicrobial therapy (OPAT): is it safe for selected patients to selfadminister at home? a retrospective analysis of a large cohort over 13 years. J Antimicrob Chemother. 2007;60:356-62.
40. Auh JS, Binns HJ, Katz BZ. Retrospective assessment of subacute or chronic osteomyelitis in children and young adults. Clin Pediatr. 2004;43:549-55.
41. Uçkay I, Lew DP. Infections in skeletal prostheses. In: Lippincott JW, editor. Bennet & Brachman's hospital infections. Philadelphia: Williams & Wilkins; 2007. p. 665-72. 39.
42. Smilack JD, Flittie WH, Williams Jr. TW. Bone concentrations of antimicrobial agents after parenteral administration. Antimicrob Agents Chemother. 1976;9:169-71.
43. Daver NG, Shelburne SA, Atmar RL, et al. Oral step-down therapy is comparable to intravenous therapy for Staphylococcus aureus osteomyelitis. J Infect. 2007;54:539-44.
44. Dellamonica P, Bernard E, Etesse H, et al. Evaluation of pefloxacin, ofloxacin and ciprofloxacin in the treatment of thirty-nine cases of chronic osteomyelitis. Eur J Clin Microbiol Infect Dis. 1989;8:1024-30.
45. Toma MB, Smith KM, Martin CA, Rapp RP. Pharmacokinetic considerations in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis. Orthopedics. 2006;29:497-501. Pharmacokinetic considerations or oral antibiotics for treatment of osteomyelitis.
46. Martini M, Adjrad A, Boudjemaa A. Tuberculous osteomyelitis. A review of 125 cases. Int Orthop. 1986;10:201-7.
47. Abgueguen P, Pichard E, Aubry J. Buruli ulcer or Mycobacterium ulcerans infection. Med Mal Infect. 2010;40:60-9.
48. Landais C, Fenollar F, Constantin A, et al. Q fever osteoarticular infection: four new cases and a review of the literature. Eur J Clin Microbiol Infect Dis. 2007;26:341-7.
49. Uçkay I, Bouchuiguir-Wafa K, Ninet B, et al. Posttraumatic ankle arthritis due to a novel Nocardia species. Infection. 2010;38:407-12.
50. Sürücüoǧlu S, El S, Ural S, et al. Evaluation of real-time PCR method for rapid diagnosis of brucellosis with different clinical manifestations. Pol J Microbiol. 2009;58:15-9.
51. Gentry LO. Antibiotic therapy for osteomyelitis. Infect Dis Clin North Am. 1990;4:485-99.
52. Lack W, McKinley T. Marjolin's ulcer: incidental diagnosis of squamous cell carcinoma on hemipelvectomy for recalcitrant pelvic osteomyelitis. Iowa Orthop J. 2010;30:174-6.
53. Eyichukwu GO, Anyaehie UE. Outcome of management of chronic osteomyelitis at National Orthopaedic Hospital, Enugu. Niger J Med. 2009;18:194-8.
54. Uçkay I, Dinh A, Vauthey L, et al. Spondylodiscitis due to Propionibacterium acnes: report of twenty-nine cases and a review of the literature. Clin Microbiol Infect. 2010;16:353-8.
55. Salvana J, Rodner C, Browner BD, et al. Chronic osteomyelitis: results obtained by an integrated team approach to management. Conn Med. 2005;69:195-202.
56. Mandell GL. The antimicrobial activity of rifampin: emphasis on the relation to phagocytes. Rev Infect Dis. 1983;5:463-7.
57. Czekaj J, Dinh A, Moldovan A, et al. Efficacy of a combined oral clindamycin-rifampicin regimen for therapy of staphylococcal osteoarticular infections. Scand J Infect Dis. 2011;43:962-7.
58. Uçkay I, Laurent F, Lustig S, et al. Hospital and communityacquired methicillin-resistant Staphylococcus aureus bone and joint infections. In: Kolendi CL, editor. Methicillin-resistant Staphylococcus aureus. Etiology, at-risk populations and treatment. New York: Nova Science Publishers; 2010. p. 143-209. 4.
59. Vuagnat A, Stern R, Lotthe A, et al. High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion. J Clin Pharm Ther. 2004;29:351-7.
60. Boffi El Amari E, Vuagnat A, Stern R, et al. High versus standard dose vancomycin for osteomyelitis. Scand J Infect Dis. 2004;36:712-7.
61. LeFrock JL, Ristuccia AM, Ristuccia PA, et al. Teicoplanin in the treatment of bone and joint infections. Eur J Surg Suppl. 1992;567:9-13.
62. Marty FM, Yeh WW, Wennersten CB, et al. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol. 2006;44:595-7.
63. Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-Aztreonam. Clin Infect Dis. 2005;41:341-53.
64. Vaudaux P, Kelley WL, Lew DP. Staphylococcus aureus small colony variants: difficult to diagnose and difficult to treat. Clin Infect Dis. 2006;43:968-70.
65. Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005;49:2260-6.
66. Bishop E, Melvani S, Howden BP, et al. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob Agents Chemother. 2006;50:1599-602.
67. Bernard L, Stern R, Lew D, Hoffmeyer P. Serotonin syndrome after concomitant treatment with linezolid and citalopram. Clin Infect Dis. 2003;36:1197.
68. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprimsulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med. 1992;117:390-8.
69. Gorwitz RJ JD, Powers JH, Jernigan JA. Strategies for clinical management of MRSA in the community: summary of an experts' meeting convened by the Centers for Disease Control and Prevention. Washington, DC; 2006.
70. Proctor RA. Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis. 2008;46:584-93.
71. Johnson MD, Decker CF. Antimicrobial agents in treatment of MRSA infections. Dis Mon. 2008;54:793-800.
72. Yourassowsky E, van der Linden MP, Lismont MJ, Crokaert F. Combination of minocycline and rifampicin against methicillinand gentamicin-resistant Staphylococcus aureus. J Clin Pathol. 1981;34:559-63.
73. Atkins B, Gottlieb T. Fusidic acid in bone and joint infections. Int J Antimicrob Agents. 1999;12:79-93.
74. Drancourt M, Stein A, Argenson JN, et al. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J Antimicrob Chemother. 1997;39:235-40.
75. Turnidge J, Collignon P. Resistance to fusidic acid. Int J Antimicrob Agents. 1999;12:35-44.
76. Darley ES, MacGowan AP. Antibiotic treatment of gram-positive bone and joint infections. J Antimicrob Chemother. 2004;53:928-35.
77. Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis. 2008;46:1069-77.
78. Lew DP, Waldvogel FA. Use of quinolones in osteomyelitis and infected orthopaedic prosthesis. Drugs. 1999;58:85-91.
79. Cordero-Ampuero J, Esteban J, Garcia-Cimbrelo E. Oral antibiotics are effective for highly resistant hip arthroplasty infections. Clin Orthop Relat Res. 2009;467:2335-42. Feasibility of oral antibiotic regimens even for arthroplasty-related osteomyelitis.
80. Greenberg RN, Newman MT, Shariaty S, Pectol RW. Ciprofloxacin, lomefloxacin, or levofloxacin as treatment for chronic osteomyelitis. Antimicrob Agents Chemother. 2000;44:164-6.
81. Nelson CL. The current status of material used for depot delivery of drugs. Clin Orthop Relat Res. 2004;427:72-8.
82. Kanellakopoulou K, Giamarellos-Bourboulis EJ. Carrier systems for the local delivery of antibiotics in bone infections. Drugs. 2000;59:1223-32.
83. Walenkamp GH, Kleijn LL, de Leeuw M. Osteomyelitis treated with gentamicin-PMMA beads: 100 patients followed for 1-12 years. Acta Orthop Scand. 1998;69:518-22.
84. Uçkay I, Assal M, Legout L, et al. Recurrent osteomyelitis caused by infection with different bacterial strains without obvious source of reinfection. J Clin Microbiol. 2006;44:1194-6.
85. Tice AD, Hoaglund PA, Shoultz DA. Risk factors and treatment outcomes in osteomyelitis. J Antimicrob Chemother. 2003;51:1261-8.
86. Panda M, Ntungila N, Kalunda M, Hinsenkamp M. Treatment of chronic osteomyelitis using the Papineau technique. Int Orthop. 1998;22:37-40.
87. Leone S, Borre S, Monforte A, et al. Consensus document on controversial issues in the diagnosis and treatment of prosthetic joint infections. Int J Infect Dis. 2010;14:67-77.
88. Simpson AH, Deakin M, Latham JM. Chronic osteomyelitis. The effect of the extent of surgical resection on infection-free survival. J Bone Joint Surg Br. 2001;83:403-7.
89. Siegel HJ, Patzakis MJ, Holtom PD, et al. Limb salvage for chronic tibial osteomyelitis: an outcomes study. J Trauma. 2000;48:484-9.
90. Seghrouchni K, van Delden C, Dominguez D, et al. Remission after treatment of osteoarticular infections due to Pseudomonas aeruginosa versus Staphylococcus aureus: a case-controlled study. Int Orthop. 2011;36:1065-71.
91. Bauer T, David T, Rimareix F, Lortat-Jacob A. Marjolin's ulcer in chronic osteomyelitis: seven cases and a review of the literature. Rev Chir Orthop Reparatrice Appar Mot. 2007;93:63-71.
92. Berendt AR, Peters EJ, Bakker K, et al. Diabetic foot osteomyelitis: a progress report on diagnosis and a systematic review of treatment. Diabetes Metab Res Rev. 2008;24:145-61. Everything you want to know about diabetic foot osteomyelitis.
93. Valabhji J, Oliver N, Samarasinghe D, et al. Conservative management of diabetic forefoot ulceration complicated by underlying osteomyelitis: the benefits of magnetic resonance imaging. Diabet Med. 2009;26:1127-34.
94. Byren I, Peters EJ, Hoey C, et al. Pharmacotherapy of diabetic foot osteomyelitis. Expert Opin Pharmacother. 2009;10:3033-47.
95. Venkatesan P, Lawn S, Macfarlane RM, et al. Conservative management of osteomyelitis in the feet of diabetic patients. Diabet Med. 1997;14:487-90.
96. Game FL, Jeffcoate WJ. Primarily non-surgical management of osteomyelitis of the foot in diabetes. Diabetologia. 2008;51:962-7. Feasibility of conservative management of chronic diabetic toe osteomyelitis.
97. Uçkay I, Vernaz-Hegi N, Harbarth S, et al. Activity and impact on antibiotic use and costs of a dedicated infectious diseases consultant on a septic orthopaedic unit. J Infect. 2009;58:205-12.